GW-590735

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H21F3N2O4S
Molecular Weight	478.484
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(SC(=N1)C2=CC=C(C=C2)C(F)(F)F)C(=O)NCC3=CC=C(OC(C)(C)C(O)=O)C=C3

InChI

InChIKey=ILUPZUOBHCUBKB-UHFFFAOYSA-N

InChI=1S/C23H21F3N2O4S/c1-13-18(33-20(28-13)15-6-8-16(9-7-15)23(24,25)26)19(29)27-12-14-4-10-17(11-5-14)32-22(2,3)21(30)31/h4-11H,12H2,1-3H3,(H,27,29)(H,30,31)

HIDE SMILES / InChI

Molecular Formula	C23H21F3N2O4S
Molecular Weight	478.484
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17243659 | https://clinicaltrials.gov/ct2/show/NCT00169559

GW 590735 is a selective and potent agonist of peroxisome proliferator-activated receptor alpha (PPARα), a ligand-activated transcription factor that plays a key role in lipid homeostasis. Activation of PPARα results in increased clearance of triglyceride (TG) rich very low-density lipoprotein. GW 590735 was in phase II clinical trial for the treatment of dyslipidemia, but that study was discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor alpha 62 Target ID: CHEMBL239 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17243659	Agonist 2678		4.0 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dyslipidemia 30 Sources: https://clinicaltrials.gov/ct2/show/NCT00169559	Primary		Phase II 1132	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
1461 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17243659	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		GW-590735 plasma	Rattus norvegicus population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17243659	2.7 mg/kg single, intravenous dose: 2.7 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		GW-590735 plasma	Rattus norvegicus population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific	1358AH	https://aksci.com/item_detail.php?cat=1358AH
ApexBio Technology	C4916	https://www.apexbt.com/catalogsearch/result/?q=C4916
BOC Sciences	622402-22-6	http://www.bocsci.com/description.asp?cas=622402-22-6
Cayman Chemical	10009880	http://www.caymanchem.com/app/template/Product.vm/catalog/10009880
MolPort	MolPort-009-019-264	https://www.molport.com/shop/molecule-link/MolPort-009-019-264
MuseChem	I007151	https://www.musechem.com/product/I007151.html
Wonderchem	WD06GQJ	http://www.wonder-chem.com/search.html?text=WD06GQJ
eMolecules	17120790	https://orderbb.emolecules.com/search/#?query=17120790

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

eight weeks treatment with 1µg to 20µg daily doses of GW590735 in otherwise healthy subjects with low HDLc, mildly to moderately elevated TG, and normal LDLc

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:43:17 UTC 2023` Edited by `admin` on `Fri Dec 15 15:43:17 UTC 2023`
Record UNII	QKY617BBX5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GW-590735

Common Name

English

PROPANOIC ACID, 2-METHYL-2-(4-((((4-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)-5-THIAZOLYL)CARBONYL)AMINO)METHYL)PHENOXY)-

Common Name

English

Code System Code Type Description

PUBCHEM

9956726